ABSTRACT
OBJECTIVE: To examine demographics and beliefs about influenza disease and vaccine that may be associated with influenza vaccination among 50- to 64-year-olds. METHODS: A national sample of adults aged 50-64 years surveyed by telephone. RESULTS: Variables associated with receiving influenza vaccination included age, education level, recent doctor visit, and beliefs about vaccine effectiveness and vaccine safety. Beliefs about influenza vaccination varied by race/ethnicity, age, education, and gender. CONCLUSION: The finding of demographic differences in beliefs suggests that segmented communication messages designed for specific demographic subgroups may help to increase influenza vaccination coverage.
Subject(s)
Culture , Health Knowledge, Attitudes, Practice , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Vaccination/statistics & numerical data , Female , Health Surveys , Humans , Influenza, Human/psychology , Male , Middle Aged , Patient Acceptance of Health Care , Population Surveillance , Socioeconomic Factors , Surveys and Questionnaires , United StatesABSTRACT
BACKGROUND: In 2006, a new rotavirus vaccine (RotaTeq) was licensed in the US and recommended for routine immunization of all US infants. Because a previously licensed vaccine (Rotashield) was withdrawn from the US for safety concerns, identifying barriers to uptake of RotaTeq will help develop strategies to broaden vaccine coverage. METHODS: We explored beliefs and attitudes of parents (n = 57) and providers (n = 10) towards rotavirus disease and vaccines through a qualitative assessment using focus groups and in-depth interviews. RESULTS: All physicians were familiar with safety concerns about rotavirus vaccines, but felt reassured by RotaTeq's safety profile. When asked about likelihood of using RotaTeq on a scale of one to seven (1 = "absolutely not;" 7 = "absolutely yes") the mean score was 5 (range = 3-6). Physicians expressed a high likelihood of adopting RotaTeq, particularly if recommended by their professional organizations and expressed specific interest in post-marketing safety data. Similarly, consumers found the RotaTeq safety profile to be favorable and would rely on their physician's recommendation for vaccination. However, when asked to rank likelihood of having their child vaccinated against rotavirus (1 = "definitely not get;" 7 = "definitely get"), 29% ranked 1 or 2, 36% 3 or 4, and 35% 5 to 7. CONCLUSION: Our qualitative assessment provides complementary data to recent quantitative surveys and suggests that physicians and parents are likely to adopt the newly licensed rotavirus vaccine. Increasing parental awareness of the rotavirus disease burden and providing physicians with timely post-marketing surveillance data will be integral to a successful vaccination program.
Subject(s)
Attitude of Health Personnel , Patient Acceptance of Health Care , Rotavirus Vaccines , Vaccines, Attenuated , Adult , Focus Groups , Humans , Parents , Patient Satisfaction , Pediatrics , Qualitative Research , SafetyABSTRACT
As scientists closely watch avian influenza A (H5N1) or "bird flu" as a potential progenitor of an influenza pandemic, researchers from the Department of Health and Human Services, Centers for Disease Control and Prevention, and Oak Ridge Institute for Science and Education conducted with focus groups with the public and interviews with healthcare providers to test pandemic influenza messages. General public findings include variable awareness of pandemic influenza, subtle changes in terms (eg, flu or influenza), and challenged communication; and "vaccine priority group" opposition to the term priority group because it meant they could be left out. Healthcare providers reported Goggle and local infectious disease specialists as dominant sources of pandemic information. The results of the study provide specific guidance for those who will develop messages about pandemic influenza for the public and healthcare provider audiences.
